Phosphodiesterase-4 (PDE4) is an intracellular pro-inflammatory enzyme that is considered a therapeutic target in inflammatory disorders such as psoriasis, asthma or ulcerative colitis (UC), among others. Researchers from Palisade Bio Inc. have reported preclinical data on PALI-2108, a PDE4 inhibitor prodrug, in models of UC.
Astrazeneca AB has synthesized fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), among others.
There are several factors that induce cirrhosis. During cirrhosis, there is an increased intrahepatic resistance to blood flow, leading to portal hypertension, among others, where portal vein pressure is increased.
Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate antitumoral immune responses, but may also induce toxicity, such as colitis, a common immune-related adverse event that can lead to treatment discontinuation.
Researchers from Hefei University and Anhui Medical University have reported the discovery of novel nitric oxide (NO) inhibitors as anti-inflammatory agents for the treatment of acute colitis.
Patients with celiac disease have gluten-specific CD4+ T cells that recognize gluten via disease-associated human leukocyte antigen (HLA) molecules, specifically HLA-DQ2.5, leading to immune activation and enteropathy.
Boehringer Ingelheim Pharma GmbH & Co. KG has identified 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Kymera Therapeutics Inc. has unveiled two new first-in-class oral degrader programs for immune-mediated diseases: KT-621, a STAT6 degrader, and KT-294, a TYK2 degrader.
RSS
